Responsive image
博碩士論文 etd-0831107-182040 詳細資訊
Title page for etd-0831107-182040
論文名稱
Title
局部投予Vasostatin眼藥水製劑在老鼠模式中之脈絡膜新生血管的緩解作用
Topical Application of Vasostatin Attenuates the Development of Choroidal Neovascularization in Rats after Laser Photocoagulation
系所名稱
Department
畢業學年期
Year, semester
語文別
Language
學位類別
Degree
頁數
Number of pages
49
研究生
Author
指導教授
Advisor
召集委員
Convenor
口試委員
Advisory Committee
口試日期
Date of Exam
2007-07-12
繳交日期
Date of Submission
2007-08-31
關鍵字
Keywords
脈絡膜新生血管、新生血管抑制劑、老年性黃斑部病變
vasostatin, choroidal neovascularization, AMD
統計
Statistics
本論文已被瀏覽 5717 次,被下載 0
The thesis/dissertation has been browsed 5717 times, has been downloaded 0 times.
中文摘要
老年性黃斑部病變是已開發國家成人致盲的主要原因,其中脈絡膜新生血管更是造成視力喪失的重要原因。脈絡膜新生血管亦可發生於高度近視、血管狀裂縫、眼發炎疾病及少數雷射後的病例,目前治療的方法包括雷射光凝法、光動力療法等,但沒有任何治療方法可根治此病。因此復發是臨床上令人困擾的問題。以外科手術移除新生血管同時也造成對視覺功能十分重要的視網膜色素上皮的損傷,因此直接針對新生血管的誘發治療應是較有效且持久的方式。
Vasostatin是一強力血管新生抑制劑,由Epstein-Barr (EB virus)病毒永生株中分離出來與鈣結合之蛋白質。在過去實驗中已發現,純化合成之Vasostatin已證明可有效抑制動物模式眼角膜新生血管的發生。同時也可抑制人類Burkitt淋巴瘤及結腸瘤在老鼠身上的生長。本研究目的在探討以局部投予Vasostatin抑制脈絡膜新生血管的生長,觀察動物模式中脈絡膜新生血管的抑制作用,並評估治療前後的視網膜功能。此計劃中,評估局部投予Vasostatin眼藥水的效果及安全性,並進而治療脈絡膜新生血管。
以上實驗結果證實局部給予Vasostatin可以緩解年齡相關性黃斑部病變或其他網膜疾病之方式。而動物實驗結果亦可作為將來臨床運用之基礎。
Abstract
Age-related macular degeneration (ARMD) is the leading cause for visual impairment and blindness in the elder population of developed countries. The primary underlying cause for significant visual loss is the choroidal neovascularization (CNV). CNV is also generated in high myopia ; angioid streaks and some inflammatory diseases and rarely after laser photocoagulation. Current treatment strategies for ARMD include laser photocoagulation , photodynamic therapy , but neither treatment addresses underlying stimuli for blood vessel growth. Therefore, recurrent disease is a problem of clinical significant relevance. Surgical excision of submacular neovascular membrane lead to the additional damage of the retinal pigment epithelium (RPE). Consequently, use of therapeutic agents that directly inhibit the angiogenic stimuli may be able to provide a more effective and permanent treatment. Vasostatin (VS) , the N-terminal domain (amino acid 1-180) of a calcium-binding protein , is a potent angiogenesis inhibitor , isolated from culture supernatants of an Epstein-Barr virus-immortalized cell line. In previous studies, we demonstrated that gene delivery of angiogenesis inhibitor vasostatin attenuated the corneal neovascularization in animals. The recombinant vasostatin also prevented or apparently reduced growth of human Burkitt lymphoma and human colon carcinoma in animal model. The primary objective of this study was to vasostatin attenuated the choroidal neovascularization in animals. Retinal and visual function will be evaluated.
The above experiments would enable us to test the hypothesis that the topical application of VS delivery might be a promising strategy for the treatment of ARMD and other retinal disorders. Furthermore, the results from animal studies might be extrapolated for future clinical application.
目次 Table of Contents
中文摘要……………………………………………………………1
英文摘要……………………………………………………………2
緒論…………………………………………………………………4
材料與方法…………………………………………………………8
結果…………………………………………………………………13
討論…………………………………………………………………16
結論…………………………………………………………………20
參考文獻……………………………………………………………21
圖表與圖解…………………………………………………………25
參考文獻 References
Reference List

1. Campochiaro PA. Retinal and choroidal neovascularization. J Cell Physiol 2000;184:301-10.
2. D'Amore PA. Mechanisms of retinal and choroidal neovascularization. Invest Ophthalmol Vis Sci 1994;35:3974-9.
3. D'Amato RJ, Adamis AP. Angiogenesis inhibition in age-related macular degeneration. Ophthalmology 1995;102:1261-2.
4. Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 2006;90:1344-9.
5. Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992;267:10931-4.
6. Pettet G, Chaplain MA, McElwain DL, Byrne HM. On the role of angiogenesis in wound healing. Proc Biol Sci 1996;263:1487-93.
7. Pettet GJ, Byrne HM, McElwain DL, Norbury J. A model of wound-healing angiogenesis in soft tissue. Math Biosci 1996;136:35-63.
8. Breier G. Angiogenesis in embryonic development--a review. Placenta 2000;21 Suppl A:S11-S15.
9. Jaffe RB. Importance of angiogenesis in reproductive physiology. Semin Perinatol 2000;24:79-81.
10. Hanahan D, Christofori G, Naik P, Arbeit J. Transgenic mouse models of tumour angiogenesis: the angiogenic switch, its molecular controls, and prospects for preclinical therapeutic models. Eur J Cancer 1996;32A:2386-93.
11. Pepper MS, Ferrara N, Orci L, Montesano R. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun 1992;189:824-31.
12. Folkman J. Diagnostic and therapeutic applications of angiogenesis research. C R Acad Sci III 1993;316:909-18.
13. Pike SE, Yao L, Jones KD, et al. Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth. J Exp Med 1998;188:2349-56.
14. Pike SE, Yao L, Setsuda J, et al. Calreticulin and calreticulin fragments are endothelial cell inhibitors that suppress tumor growth. Blood 1999;94:2461-8.
15. Yao L, Pike SE, Setsuda J, et al. Effective targeting of tumor vasculature by the angiogenesis inhibitors vasostatin and interleukin-12. Blood 2000;96:1900-5.
16. Sheu SJ, Chou LC, Bee YS, et al. Suppression of choroidal neovascularization by intramuscular polymer-based gene delivery of vasostatin. Exp Eye Res 2005;81:673-9.
17. Wu PC, Yang LC, Kuo HK, et al. Inhibition of corneal angiogenesis by local application of vasostatin. Mol Vis 2005;11:28-35.
18. Miller JW, Schmidt-Erfurth U, Sickenberg M, et al. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in a phase 1 and 2 study. Arch Ophthalmol 1999;117:1161-73.
19. Algvere PV, Seregard S. Age-related maculopathy: pathogenetic features and new treatment modalities. Acta Ophthalmol Scand 2002;80:136-43.
20. Edelman JL, Castro MR. Quantitative image analysis of laser-induced choroidal neovascularization in rat. Exp Eye Res 2000;71:523-33.
21. Hermans P, Lommatzsch A, Bomfeld N, Pauleikhoff D. [Angiographic-histological correlation of late exudative age-related macular degeneration]. Ophthalmologe 2003;100:378-83.
22. Horle S, Postgens H, Schmidt J, Kroll P. Pigment epithelium defects after submacular surgery for choroidal neovascularization: first results. Ophthalmologica 2000;214:122-5.
23. Emerson MV, Lauer AK, Flaxel CJ, et al. Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration. Retina 2007;27:439-44.
24. Rodrigues EB, Rossi EE, Grumann JA, et al. [Treatment of neovascular age-related macular degeneration with antiangiogenic drugs]. Arq Bras Oftalmol 2006;69:756-65.
25. Tobin KA. Macugen treatment for wet age-related macular degeneration. Insight 2006;31:11-4.
電子全文 Fulltext
本電子全文僅授權使用者為學術研究之目的,進行個人非營利性質之檢索、閱讀、列印。請遵守中華民國著作權法之相關規定,切勿任意重製、散佈、改作、轉貼、播送,以免觸法。
論文使用權限 Thesis access permission:校內校外均不公開 not available
開放時間 Available:
校內 Campus:永不公開 not available
校外 Off-campus:永不公開 not available

您的 IP(校外) 位址是 44.199.241.53
論文開放下載的時間是 校外不公開

Your IP address is 44.199.241.53
This thesis will be available to you on Indicate off-campus access is not available.

紙本論文 Printed copies
紙本論文的公開資訊在102學年度以後相對較為完整。如果需要查詢101學年度以前的紙本論文公開資訊,請聯繫圖資處紙本論文服務櫃台。如有不便之處敬請見諒。
開放時間 available 已公開 available

QR Code